Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Business context and period: This is the unaudited fiscal first-quarter report for the three months ended December 31, 2020, compared with the three months ended December 31, 2019. Citius is a development-stage specialty pharmaceutical company with no product revenue. Its programs include Mino-Lok, Mino-Wrap and Halo-Lido; majority-owned NoveCite is developing a stem-cell therapy for acute respiratory distress syndrome (ARDS).
Financial performance and position
| Metric | Quarter ended Dec. 31, 2020 | Prior-year quarter / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $6.19 million | $2.66 million; up $3.53 million |
| General and administrative expense | $1.69 million | $1.56 million; up $0.13 million |
| Total operating expenses / operating loss | $8.16 million / $(8.16) million | $4.45 million / $(4.45) million |
| Net loss | $(8.15) million | $(4.32) million; loss increased $3.82 million |
| Basic and diluted loss per share | $(0.15) | $(0.15); weighted-average shares increased from 29.20 million to 55.58 million |
| Net cash used in operating activities | $(9.56) million | $(5.11) million |
| Cash and cash equivalents | $4.30 million at Dec. 31, 2020 | $13.86 million at Sept. 30, 2020 |
| Working capital | $2.03 million at Dec. 31, 2020 | — |
| Total liabilities | $9.51 million at Dec. 31, 2020 | $10.10 million at Sept. 30, 2020 |
Revenue and operating margins are not meaningful because the company had no revenue. Cash declined by $9.56 million during the quarter. The balance sheet included $0.17 million of related-party notes payable and a $0.16 million PPP loan; it also included $0.98 million of operating lease liabilities. The filing does not provide a conventional debt-to-capital measure.
Material changes and notable items
- R&D expense rose 132% year over year, primarily reflecting $5.24 million of ARDS-program costs, including the $5.0 million NoveCite license payment to Novellus. Mino-Lok R&D fell to $0.72 million from $2.11 million; Halo-Lido R&D fell to $0.23 million from $0.55 million.
- In October 2020, NoveCite licensed cellular-therapy technology from Novellus, paid $5.0 million and issued Novellus 25% of NoveCite’s equity; Citius owns 75%. The license provides for up to $51 million in development and regulatory milestones, royalties and a share of sublicense fees.
- Other income was zero versus $0.11 million in the prior-year quarter, when the company recorded an FDA fee refund. This also contributed to the higher year-over-year net loss.
- At December 31, 2020, Citius had 26.75 million warrants outstanding. Options and warrants represent potential future dilution.
Outlook, liquidity and risks
- Management estimated that year-end cash plus proceeds from a subsequent January 2021 private placement would fund operations through September 2021. The filing nevertheless states that substantial doubt exists about the company’s ability to continue as a going concern. Citius has no operating revenue and expects to seek additional capital; there is no assurance it can obtain sufficient funding on acceptable terms.
- On January 27, 2021, after quarter-end, the company closed a private placement raising approximately $20 million gross through common shares and warrants. In February 2021, it also received $4.51 million net from the exercise of 3,921,569 warrants. These subsequent proceeds were not included in December 31 cash.
- Management expects R&D spending to increase in fiscal 2021 as it focuses on the Mino-Lok Phase 3 trial and advances Halo-Lido, ARDS and Mino-Wrap. No specific trial milestones or revenue guidance are provided in this filing.
- Key risks include further financing needs, clinical development cost, timing and results, regulatory approval, commercial feasibility, and reliance on personnel, suppliers and strategic partners. The company reported no change to the risk factors in its latest Form 10-K, no legal proceedings, and effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Whether the January financing and subsequent warrant proceeds, together with ongoing cash burn, support the company’s stated runway and planned clinical programs.
- Current status, timelines and funding requirements for the Mino-Lok Phase 3 trial and the Halo-Lido, Mino-Wrap and NoveCite programs.
- Potential dilution from outstanding warrants, options and future financing, including the post-quarter private placement.
- Terms and potential financial impact of NoveCite’s Novellus license, including milestone obligations, royalties and Novellus’s equity ownership protections.